Devereaux P J, Beattie W Scott, Choi Peter T-L, Badner Neal H, Guyatt Gordon H, Villar Juan C, Cinà Claudio S, Leslie Kate, Jacka Michael J, Montori Victor M, Bhandari Mohit, Avezum Alvaro, Cavalcanti Alexandre B, Giles Julian W, Schricker Thomas, Yang Homer, Jakobsen Carl-Johan, Yusuf Salim
Department of Medicine, McMaster University, Hamilton, ON, Canada.
BMJ. 2005 Aug 6;331(7512):313-21. doi: 10.1136/bmj.38503.623646.8F. Epub 2005 Jul 4.
To determine the effect of perioperative beta blocker treatment in patients having non-cardiac surgery.
Systematic review and meta-analysis.
Seven search strategies, including searching two bibliographic databases and hand searching seven medical journals. STUDY SELECTION AND OUTCOMES: We included randomised controlled trials that evaluated beta blocker treatment in patients having non-cardiac surgery. Perioperative outcomes within 30 days of surgery included total mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal cardiac arrest, non-fatal stroke, congestive heart failure, hypotension needing treatment, bradycardia needing treatment, and bronchospasm.
Twenty two trials that randomised a total of 2437 patients met the eligibility criteria. Perioperative beta blockers did not show any statistically significant beneficial effects on any of the individual outcomes and the only nominally statistically significant beneficial relative risk was 0.44 (95% confidence interval 0.20 to 0.97, 99% confidence interval 0.16 to 1.24) for the composite outcome of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal cardiac arrest. Methods adapted from formal interim monitoring boundaries applied to cumulative meta-analysis showed that the evidence failed, by a considerable degree, to meet standards for forgoing additional studies. The individual safety outcomes in patients treated with perioperative beta blockers showed a relative risk for bradycardia needing treatment of 2.27 (95% CI 1.53 to 3.36, 99% CI 1.36 to 3.80) and a nominally statistically significant relative risk for hypotension needing treatment of 1.27 (95% CI 1.04 to 1.56, 99% CI 0.97 to 1.66).
The evidence that perioperative beta blockers reduce major cardiovascular events is encouraging but too unreliable to allow definitive conclusions to be drawn.
确定围手术期β受体阻滞剂治疗对接受非心脏手术患者的影响。
系统评价和荟萃分析。
七种检索策略,包括检索两个文献数据库和手工检索七种医学期刊。研究选择和结果:我们纳入了评估β受体阻滞剂治疗非心脏手术患者的随机对照试验。手术30天内的围手术期结局包括总死亡率、心血管死亡率、非致命性心肌梗死、非致命性心脏骤停、非致命性中风、充血性心力衰竭、需要治疗的低血压、需要治疗的心动过缓和支气管痉挛。
共有2437例患者被随机分组的22项试验符合纳入标准。围手术期β受体阻滞剂对任何个体结局均未显示出任何统计学上显著的有益效果,对于心血管死亡率、非致命性心肌梗死和非致命性心脏骤停的综合结局,唯一名义上具有统计学显著意义的有益相对风险为0.44(95%置信区间0.20至0.97,99%置信区间0.16至1.24)。采用适用于累积荟萃分析的正式中期监测界限的方法显示,证据在很大程度上未能达到放弃进一步研究的标准。围手术期接受β受体阻滞剂治疗患者的个体安全性结局显示,需要治疗的心动过缓的相对风险为2.27(95%CI 1.53至3.36,99%CI 1.36至3.80),需要治疗的低血压的名义上具有统计学显著意义的相对风险为1.27(95%CI 1.04至1.56,99%CI 0.97至1.66)。
围手术期β受体阻滞剂可降低主要心血管事件的证据令人鼓舞,但可靠性不足,无法得出明确结论。